Cytomos has secured £1.6m in funding to progress the development and qualification of its novel cell analysis platform, Cytomos Dielectric Spectroscopy (CDS).
The seed round was led by existing investor Archangels, with participation from Scottish Enterprise and Old College Capital.
The Edinburgh-based life science company has developed a proprietary new approach to analysing cells, aiming to address the unmet needs of the biopharma industry, providing a low-cost, portable and scalable alternative.
